6-chloro-3-(propan-2-yl)-1H-indazole | 1415740-55-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 6-chloro-3-(propan-2-yl)-1H-indazole
• 英文别名: 6-Chloro-3-isopropyl-1H-indazole；6-chloro-3-propan-2-yl-2H-indazole
• CAS: 1415740-55-4
• 化学式: C₁₀H₁₁ClN₂
• 分子量: 194.664
• InChiKey: GJCSGBQFUZQYFI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE
  申请人：Lycera Corporation

  公开号：US20150119439A1

  公开（公告）日：2015-04-30

  The invention provides saturated acyl guanidine compounds that inhibit F 1 F 0 -ATPase, and methods of using saturated acyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

  该发明提供了饱和脂肪酰基胍化合物，可以抑制F1F0-ATP酶，并且使用饱和脂肪酰基胍化合物作为治疗剂治疗医疗障碍的方法，例如免疫障碍、炎症状况或癌症。
• INDAZOLE GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF
  申请人：Lycera Corporation

  公开号：US20150152063A1

  公开（公告）日：2015-06-04

  The invention provides indazole guanidine compounds that inhibit F 1 F 0 -ATPase, and methods of using indazole guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

  该发明提供了一种抑制F1F0-ATP酶的吲唑胍化合物，并使用吲唑胍化合物作为治疗剂治疗医学疾病，例如免疫紊乱、炎症病症或癌症的方法。
• SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE
  申请人：PETRUKHIN Konstantin

  公开号：US20150315197A1

  公开（公告）日：2015-11-05

  The present invention provides a compound having the structure: wherein R 1 , R 2 , R 3 , R 4 , and R 5 are each independently H, halogen, CF 3 or C 1 -C 4 alkyl, wherein two or more of R 1 , R 2 , R 3 , R 4 , or R 5 are other than H; R 6 is H, OH, or halogen; and B is a substituted or unsubstituted heterobicycle, wherein when R 1 is CF 3 , R 2 is H, R 3 is F, R 4 is H, and R 5 is H, or R 1 is H, R 2 is CF 3 , R 3 is H, R 4 is CF 3 , and R 5 is H, or R 1 is Cl, R 2 is H, R 3 is H, R 4 is F, and R 5 is H, or R 1 is CF 3 , R 2 is H, R 3 is F, R 4 is H, and R 5 is H, or R 1 is CF 3 , R 2 is F, R 3 is H, R 4 is H, and R 5 is H, or R 1 is Cl, R 2 is F, R 3 is H, R 4 is H, and R 5 is H, then B is other than or a pharmaceutically acceptable salt thereof.

  本发明提供了一种具有以下结构的化合物：其中R1、R2、R3、R4和R5各自独立地为H、卤素、CF3或C1-C4烷基，其中R1、R2、R3、R4或R5中的两个或更多个不是H；R6为H、OH或卤素；B为取代或未取代的杂环，其中当R1为 、R2为H、R3为F、R4为H和R5为H，或者R1为H、R2为 、R3为H、R4为 和R5为H，或者R1为Cl、R2为H、R3为H、R4为F和R5为H，或者R1为 、R2为H、R3为F、R4为H和R5为H，或者R1为 、R2为F、R3为H、R4为H和R5为H，或者R1为Cl、R2为F、R3为H、R4为H和R5为H时，则B不是或其药学上可接受的盐。
• OCTAHYDROCYCLOPENTAPYRROLES, THEIR PREPARATION AND USE
  申请人：PETRUKHIN Konstantin

  公开号：US20160024007A1

  公开（公告）日：2016-01-28

  The present invention provides Octahydrocyclopentapyrrole compounds having the structure: (structurally represented) wherein psi is absent or present, and when present is a bond; R1, R2, R3, R4, and R5 are each independently H, halogen, CF, or C1-C4 alkyl; R6 is absent or present, and when present is H, OH, or halogen; A is absent or present, and when present is C(O) or C(O)NH; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is C(O); and when psi is present, then R6 is absent and when psi is absent, then R6 is present, or a pharmaceutically acceptable salt thereof, for treatment of diseases characterized by excessive lipofuscin accumulation in the retina.

  本发明提供了八氢环戊吡咯化合物，其结构如下：（结构式表示），其中psi不存在或存在，当存在时为键；R1、R2、R3、R4和R5各自独立地为H、卤素、CF或C1-C4烷基；R6不存在或存在，当存在时为H、OH或卤素；A不存在或存在，当存在时为C（O）或C（O）NH；B为取代或未取代的单环、双环、杂单环、杂双环、苄基、CO2H或（C1-C4烷基）-CO2H，其中当B为CO2H时，A存在且为C（O）；当psi存在时，R6不存在，当psi不存在时，R6存在，或其药学上可接受的盐，用于治疗以视网膜过多脂褐质沉积为特征的疾病。
• N-alkyl-2-phenoxyethanamines, their preparation and use
  申请人：The Trustees of Columbia University In the City of New York

  公开号：US10570148B2

  公开（公告）日：2020-02-25

  The present invention provides a compound having the structure: (structurally represented) wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl; R6 is alkyl; A is absent or present, and when present is —C(O)— or —C(O)NH—; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is —C(O)—, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种具有以下结构的化合物：(结构表示），其中 R1、R2、R3、R4 和 R5 各自独立地为 H、卤素、CF3 或 C1-C4 烷基；R6 为烷基；A 不存在或存在，存在时为 -C(O)- 或 -C(O)NH- ；B 为取代或未取代的单环、单车、杂单环、杂单车、苄基、CO2H 或 (C1-C4 烷基)-CO2H，其中当 B 为 CO2H 时，则 A 存在且为 -C(O)-，或其药学上可接受的盐。